[1] Rajesh P P. Nonketotic Hyperglycinemia: Two Case Reports and Review[J]. The Neurodiagnostic journal, 2019, 59(3): 142-151.
[2] Zhou B B, Hui L, Zhang Q H, et al. The Mutation Analysis of the AMT Gene in a Chinese Family With Nonketotic Hyperglycinemia[J]. Front Genet, 2022, 13: 854712.
[3] Curtis R C. The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT[J]. Genetics in medicine : official journal of the American College of Medical Genetics, 2017, 19(1): 104-111.
[4] Poothrikovil R P, Thihli K A, Futaisi A A, et al. Nonketotic Hyperglycinemia: Two Case Reports and Review[J]. The Neurodiagnostic journal, 2019, 59(3): 1-10.
[5] Perry T L, Urquhart N, Maclean J, et al. Nonketotic hyperglycinemia. Glycine accumulation due to absence of glycerine cleavage in brain[J]. N Engl J Med, 1975, 292(24): 1269-73.
[6] Hennermann J B, Berger J M, Grieben U, et al. Prediction of long-term outcome in glycine encephalopathy: a clinical survey[J]. Journal of Inherited Metabolic Disease, 2012, 35(2): 253-261.
[7] A Y T C, C W D L B, A Z N C, et al. Nonketotic hyperglycinemia: A case report and brief review - ScienceDirect[J]. BioMedicine, 2012, 2(2): 80-82.
[8] Sel C G, Mustafayuksel, Denizaksoy, Aysekasapkara, Cigdem Seherceylaner, Serdaroguz, Kader Karli. Nonketotic hyperglycinemia: Clinical range and outcome of a rare neurometabolic disease in a singlecenter[J]. Brain & Development, 2018, 40(10).
[9] Mcadams R M, Richards T L. Detection of nonketotic hyperglycinemia in a neonate using proton magnetic resonance spectroscopy[J]. Radiology Case Reports, 2009, 38(2): 19-28.
[10] P B. A known and a novel mutation in the glycine decarboxylase gene in a newborn with classic nonketotic hyperglycinemia[J]. Neuropediatrics, 2012, 43(3): 164-7.
[11] Swanson M A, Coughlin C R, Scharer G H, et al. Biochemical and molecular predictors for prognosis in nonketotic hyperglycinemia[J]. Annals of Neurology, 2015, 78(4): 606-618.
[12] Korman S H, Boneh A, Ichinohe A, et al. Persistent NKH with transient or absent symptoms and a homozygous GLDC mutation[J]. Annals of Neurology, 2015, 42(1): 23-29.
[13] Nowak M, Chuchra P, Paprocka J. Nonketotic Hyperglycinemia: Insight into Current Therapies[J]. J Clin Med, 2022, 11(11): 50-58.
[14] V. S N. Brain imaging in classic nonketotic hyperglycinemia:Quantitative analysis and relation to phenotype[J]. Journal of inherited metabolic disease, 2019, 42(3): 438-450.
[15] Stence N V, Fenton L Z, Levek C, et al. Brain imaging in classic nonketotic hyperglycinemia: Quantitative analysis and relation to phenotype[J]. J Inherit Metab Dis, 2019, 42(3): 438-450.
[16] Yuka S. Nonketotic hyperglycinemia: proposal of a diagnostic and treatment strategy[J]. Pediatric neurology, 2010, 43(3): 221-4.
[17] Van Hove J L K. The role of NMDA-receptor type glutamatergic antagonists dextromethorphan or ketamine in the treatment of nonketotichyperglycinemia: A critical reassessment[J]. Mol Genet Metab, 2024, 143(3): 108594.
[18] Leipnitz G, Da Rosa J S, Wajner M. The Role of Excitotoxicity, Oxidative Stress and Bioenergetics Disruption in the Neuropathology of Nonketotic Hyperglycinemia[J]. Neurotox Res, 2024, 42(4): 32.